Advanced Analysis Free Trading Signals Real Time Alerts

Progenity (PROG) Stock Falls After Announcing $40m Offering Pricing

Practice Stock Trading Your Capital Is At Risk
Updated: 20 Aug 2021

Progenity Inc (NASDAQ: PROG) shares have plunged premarket after the company announced the pricing of its public offering of 40 million shares and warrants.

The biotechnology company is selling one share and one warrant for $1. The warrants will have an exercise price of $1 per share and are exercisable immediately, with an expiration date expire five years after the issuance.

Additionally, the company has granted the underwriter a 30-day option to purchase up to 6,000,000 shares of common stock and warrants at the public offering price.


The San Diego-based firm is expecting to receive proceeds of approximately $40 million.

Progenity shares have plunged 51.6% to $0.72 premarket. In 2021 its shares have declined 71.94%. The company went public in June 2020, pricing its IPO at $15 per share. Since then it has been mostly downhill for Progenity's share price, losing 84.4% of its value in the last 12 months.

Should You Invest in Progenity Shares?

Based on its recent price movement, Progenity shares don't look attractive. However, one of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .